교수진 소개
- Name
- Ho Jin KIM, M.D., Ph.D. (adjunct professor)
- Faculty Appointment
(title, department)
- Professor, Department of Cancer Biomedical Science
- Area of Expertise
- Neuro-immunology & Neuro-oncology
- E-mail
- hojinkim@ncc.re.kr
- Work Experience
- Chief of Specific Organ Cancer Branch (2014-present)
Head of Department of Neurology (2005-present)
Head of Center for Clinical Specialty (2009-2012)
Head of Center for Clinical Support (2007-2009)
- Educational Background
- MD, Seoul National University, College of Medicine
MSc, Seoul National University, College of Medicine
PhD, Seoul National University, College of Medicine
Post-doctoral fellow, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA
Post-doctoral fellow, Montreal Neurological Institute of McGill University, Montreal, Quebec, Canada
- Research Interests (Please place in paragraph form)
- My major research interests lie in studying the development and application of biological assays for CNS autoimmune diseasesto monitor the disease processand to evaluate the response to novel therapeutics. Additionally, I’m interested in studying differences between multiple sclerosis and neuromyelitisoptica in both clinical spectrum and treatment response as well as underlying pathogenesis. My other research interest is in studying thecellular and molecular mechanisms involved in transmigration of caner cells across the blood-brain barrier.
- International Collaboration
- American Academy of Neurology
The Federation of Clinical Immunology Societies
European Neurological Society
Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS)
European Committee for Treatment and Research in Multiple Sclerosis (ECACTRIMS)
NeuromyelitisOpticaInternational Clinical Consortium and Biorepository
- Achievements
-
2022 SCI-E Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: Large multi-ethnic population and different clinical scenarios: MULTIPLE SCLEROSIS AND RELATED DISORDERS. :~ (4.339)
2022 SCI-E Onset of various CNS inflammatory demyelination diseases following COVID-19 vaccinations: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 68:104141~ (4.808)
2022 SCI-E Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers: FRONTIERS IN ONCOLOGY. 12:942960~ (5.738)
2022 SCI-E Seroprevalence of anti-myelin oligodendrocyte glycoprotein antibodies in adults with myelitis: ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY. 9(9):1481~1486 (5.43)
2022 기타 A 24-Year-Old Woman Presenting with Decreased Visual Acuity and Pain on Left Eye: 대한신경과학회지. 40(3):280~286 (0)
2022 SCI-E Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders A 14-Year Real-Life Experience: NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 9(5):e1179 ~ (11.36)
2022 SCI-E Effect of Combined Intravenous Immunoglobulin and Mycophenolate Mofetil in a Pediatric Patient With Highly Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: JOURNAL OF CLINICAL NEUROLOGY. 18(4):495~497 (2.566)
2022 SCI-E Clinical and Radiological Features of Myelin Oligodendrocyte Glycoprotein-Associated Myelitis in Adults: JOURNAL OF CLINICAL NEUROLOGY. 18(3):280~289 (2.566)
2022 SCI-E CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage: JOURNAL OF NEUROINFLAMMATION. 19(1):86~ (9.587)
2022 SCI-E Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody associated disease: JAMA NEUROLOGY. 79(5):518~525 (29.907)
2022 SCI-E Results of a Survey on Diagnostic Procedures and Treatment Choices for Neuromyelitis Optica Spectrum Disorder in Korea: Beyond the Context of Current Clinical Guidelines: JOURNAL OF CLINICAL NEUROLOGY. 18(2):207~213 (2.566)
2022 SCI-E Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: Longitudinal assessment of serum neurofilament light chain: MULTIPLE SCLEROSIS JOURNAL. Online:Published (6.312)
2022 SCI-E AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 57:103356~ (4.339)
2021 SCI-E Guillain-Barre syndrome after vaccination against COVID-19: LANCET NEUROLOGY. 21(2):117~119 (44.182)
2021 SCI-E Demystifying MOGAD and Double Seronegative NMOSD Further With IL-6 Blockade.: NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 9(1):e1110~ (8.485)
2021 SCI-E Functional impairment of CD19+CD24hiCD38hi B cells in neuromyelitis optica spectrum disorder is restored by B cell depletion therapy.: SCIENCE TRANSLATIONAL MEDICINE. 13(624):eabk2132~ (17.992)
2021 SCI-E Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD: MULTIPLE SCLEROSIS JOURNAL. Online:Published (6.312)
2021 SCI-E Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study: MULTIPLE SCLEROSIS AND RELATED DISORDERS. Online:Published (4.339)
2021 SCI-E Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists: MULTIPLE SCLEROSIS AND RELATED DISORDERS. Online:Published (4.339)
2021 SCI-E Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. :jnnp-2021-327412~ (10.283)
2021 SCI-E Reappraisal of CSF-specific oligoclonal bands in Asia: MULTIPLE SCLEROSIS JOURNAL. Online:Published (6.312)
2021 SCI-E Retinal Optical Coherence Tomography in Neuromyelitis Optica: NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 8(6):e1068~ (8.485)
2021 SCI-E A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica: ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY. 8(10):2025~2037 (4.511)
2021 SCI-E Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension: MULTIPLE SCLEROSIS JOURNAL. Online:Published (6.312)
2021 SCI-E Myelin-oligodendrocyte glycoprotein antibody-associated disease.: LANCET NEUROLOGY. 20(9):762~772 (44.182)
2021 SCI-E Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis: FRONTIERS IN NEUROLOGY. 12:714941~ (4.003)
2021 SCI-E Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.: NEUROLOGY AND THERAPY. Online:Published (5.814)
2021 SCI-E Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 53:103080~ (4.339)
2021 SCI-E Evaluation of Serum neurofilament light chain and glial fibrillary acidic protein as screening and monitoring biomarkers for brain metastases: CANCERS. 13(9):2227~ (6.639)
2021 기타 Investigation of serum biomarkers for neuropathic pain in neuromyelitis optica spectrum disorder: a preliminary study: Annals of clinical neurophysiology. 23(1):46~52 (0)
2021 SCI-E Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 8(3):e965~ (8.485)
2021 SCI-E Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder: NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 8(3):e978~ (8.485)
2021 SCI-E Altered distributions in circulating follicular helper and follicular regulatory T cells accountable for imbalanced cytokine production in multiple sclerosis: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. Online:Published (4.33)
2021 SCI-E Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aqauporin-4 antibodies: NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 8(2):e947~ (8.485)
2021 SCI-E Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 50:102849~ (4.339)
2021 SCI-E Long-term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD: ANNALS OF NEUROLOGY. 89(6):1088~1098 (10.422)
2021 SCI-E Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.: MULTIPLE SCLEROSIS JOURNAL. :1~10 (6.312)
2021 SCI-E The influence of smoking on the pattern of disability and relapse risk in AQP4-positive neuromyelitis optica spectrum disorder, MOG-Ab disease and multiple sclerosis: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 49:102773~ (4.339)
2021 기타 Sleep Related Disorders and Inflammatory Diseases of the Central Nervous System: Journal of Sleep Medicine. 17(2):108~112 (0)
2021 SCI-E Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 47:102641~ (2.889)
2020 기타 Cost Effectiveness of First-Line Rituximab in Koreans with Neuromyelitis Optica Spectrum Disorder: 대한신경면역학회지. 11(2):53~58 (0)
2020 SCI-E Benefits of eculizumab in AQP4C neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 47:102641~ (2.889)
2020 SCI-E Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO): BMJ OPEN. 10(10):e035397~ (2.496)
2020 SCI-E Neuromyelitis optica: NATURE REVIEWS DISEASE PRIMERS. Online:Published (40.689)
2020 SCI-E Nanoparticles in 472 human cerebrospinal fluid: Changes in extracellular vesicle concentration and miR-21 expression as a biomarker for leptomeningeal metastasis: CANCERS. 12(10):E2745~ (6.126)
2020 SCI-E Incidence of inter-attack asymptomatic brain lesions in NMO spectrum disorder: NEUROLOGY. 95(23):e3124~e3128 (8.77)
2020 SCI-E Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases: MULTIPLE SCLEROSIS JOURNAL. Online:Published (5.412)
2020 SCI-E Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Associated Disease in Korean Children: JOURNAL OF CLINICAL NEUROLOGY. 16(3):461~469 (2.439)
2020 SCI-E Value of Area Postrema Syndrome in Differentiating Adults with AQP4 vs. MOG Antibodies: FRONTIERS IN NEUROLOGY. Online:Published (2.889)
2020 SCI-E Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 44:102251~ (2.889)
2020 SCI-E Disease modifying therapies and infection risks in multiple sclerosis?a decision-making conundrum: ANNALS OF TRANSLATIONAL MEDICINE. 8(11):722~ (3.297)
2020 SCI-E Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy: SCIENTIFIC REPORTS. 10(1):7995~ (3.998)
2020 SCI-E CYFRA 21-1 levels in cerebrospinal fluid as a putative therapeutic monitoring biomarker for patients with leptomeningeal carcinomatosis: A pilot study: CANCER BIOMARKERS. 28(1):81~89 (3.436)
2020 SCI-E outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder: EUROPEAN JOURNAL OF NEUROLOGY. Online:Published (4.516)
2020 SCI-E Recurrence of clinical events at the same anatomical location in patients with MOG antibody-associated disease: MULTIPLE SCLEROSIS JOURNAL. Online:Published (5.412)
2020 SCI-E Smelling the danger: MULTIPLE SCLEROSIS JOURNAL. Online:Published (5.412)
2020 SCI-E Validation of the Korean Version of the 12-Item Multiple Sclerosis Walking Scale and Application to Neuromyelitis Optica Spectrum Disorder: JOURNAL OF CLINICAL NEUROLOGY. 16(2):270~276 (2.439)
2020 SCI-E Monoclonal Antibody Therapies for Multiple Sclerosis and Nuromyelitis Optica Spectrum Disorder: JOURNAL OF CLINICAL NEUROLOGY. 16(3):355~368 (2.439)
2020 SCI-E MSJ 2020 - Editorial comment: MULTIPLE SCLEROSIS JOURNAL. 26(2):134~ (5.412)
2020 SCI-E So You Want to Image Myelin Using MRI: An Overview and Practical Guide for Myelin Water Imaging: JOURNAL OF MAGNETIC RESONANCE IMAGING. Online:Published (3.954)
2020 SCI-E Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases.: MULTIPLE SCLEROSIS AND RELATED DISORDERS. Online:Published (2.889)
2020 SCI-E Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis: Journal of clinical neurology. 16(1):124~130 (2.439)
2019 SCI Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies: Multiple Sclerosis Journal. Online:Published (5.649)
2019 SCI Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea: Multiple Sclerosis Journal. Online:Published (5.649)
2019 SCI-E Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab: Neurology Neuroimmunology Neuroinflammation. 1:635~635 (7.353)
2019 SCI-E Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma: Clinical Lung Cancer. 19:30282~30287 (4.117)
2019 SCI-E Retinal Degeneration After First-Ever Optic Neuritis Helps Differentiate Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Frontiers in Neurology. Online:Published (2.635)
2019 SCI-E High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis: Journal of clinical neurology. 15(4):454~460 (2.796)
2019 SCI-E Changing patterns of multiple sclerosis in Korea: Toward a more baseline MRI lesions and intrathecal humoral immune responses: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 35:209~214 (2.725)
2019 SCI Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial: LANCET. Online:Published (59.102)
2019 SCI-E Therapeutic Outcome of Alemtuzumab in Korean Patients with Multiple Sclerosis: 2-Year Follow-Up: JOURNAL OF CLINICAL NEUROLOGY. 15(3):328~333 (2.796)
2019 SCI Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder: THE NEW ENGLAND JOURNAL OF MEDICINE. Online:Published (70.67)
2019 기타 Cerebrospinal Fluid CYFRA 21-1 as a Diagnostic Indicator for Leptomeningeal Metastasis in Cancer Patients: Journal of the Korean Neurological Association. 37(2):161~165 (0)
2019 SCI Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis: MULTIPLE SCLEROSIS : CLINICAL AND LABORATORY RESEARCH. Online:Published (5.649)
2019 SCI-E Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions: Multiple Sclerosis and Related Disorders. 28:64~68 (3.199)
2019 SCI Integrative metabolomics reveals unique metabolic traits in Guillain-Barre Syndrome and its variants: SCIENTIFIC REPORTS. 9(1):1077~1077 (4.011)
2018 SCI-E Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder: Neurochemistry International. Online:Published (3.603)
2018 기타 Rituximab in neurological disease: principles, evidence and practice: Practical Neurology. Online:Published (0)
2018 SCI Racial differences in neuromyelitis optica spectrum disorder: Neurology. 91(22):e2089~e2099 (8.055)
2018 SCI Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis: MULTIPLE SCLEROSIS : CLINICAL AND LABORATORY RESEARCH. Online:Published (5.28)
2018 SCI-E Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis: JOURNAL OF NEUROINFLAMMATION. 15(1):300~300 (5.193)
2018 SCI-E Real-world effectiveness of disease-modifying therapies in Korean patients with relapsing multiple sclerosis: JOURNAL OF CLINICAL NEUROLOGY. Online:Published (2.851)
2018 SCI-E Evaluation of Normal-Appearing White Matter in Multiple Sclerosis Using Direct Visualization of Short Transverse Relaxation Time Component (ViSTa) Myelin Water Imaging and Gradient Echo and Spin Echo (GRASE) Myelin Water Imaging: Journal of Magnetic Resonance Imaging. Online:Published (3.612)
2018 SCI Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome: Multiple sclerosis : clinical and laboratory research. Online:Published (5.28)
2018 SCI Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment.: Journal of neurology, neurosurgery and psychiatry. Online:Published (7.144)
2018 SCI-E MOG encephalomyelitis: International recommendations on diagnosis and antibody testing: Journal of neuroinflammation. 15(1):134~134 (5.193)
2018 SCI-E Neutralizing Antibodies against Interferon-beta in Korean Patients with Multiple Sclerosis: Journal of clinical neurology. 14(2):186~190 (2.851)
2018 SCI-E Optical Coherence Tomography versus Visual Evoked Potentials for Detecting Visual Pathway Abnormalities in Patients with Neuromyelitis Optica Spectrum Disorder: Journal of clinical neurology. 14(2):200~205 (2.851)
2018 SCI Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis: Multiple sclerosis : clinical and laboratory research. Online:Published (5.28)
2018 SCI-E A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy: Journal of Clinical Neurology. 14(1):81~89 (2.593)
2017 SCI-E Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders: Multiple sclerosis : clinical and laboratory research.. 24(13):1737~1742 (4.84)
2017 SCI Evaluation of 2016 MAGNIMS MRI criteria for dissemination in space in patients with a clinically isolated syndrome: Multiple sclerosis. 24(6):758~766 (4.84)
2017 SCI Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.: Multiple Sclerosis. 23(14):1902~1908 (4.84)
2017 SCI Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases: Journal of Neurology, Neurosurgery, Psychiatry. 88(10):811~817 (7.349)
2017 SCI-E Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder: Journal of neuroinflammation. 14(1):191~191 (5.102)
2017 SCI Immune checkpoint inhibitor therapy: A double-edged sword?: Neurology. 89(11):1101~1102 (7.592)
2017 SCI Multimodal magnetic resonance imaging in relation to cognitive impairment in neuromyelitis optica spectrum disorder: Scientific Reports. 7(1):9180~9180 (4.259)
2017 SCI-E Diagnostic and prognostic values of cerebrospinal fluid CYFRA 21-1 in patients with leptomeningeal carcinomatosis: Oncotarget. 8(32):53326~53335 (5.168)
2017 SCI A step forward towards personalised immunosuppressive therapy in neuromyelitis optica spectrum disorder: Journal of Neurology, Neurosurgery and Psychiatry. 88(8):619~619 (7.349)
2017 SCI De novo cystic brain lesions mimicking neurocysticercosis in ALK-positive lung cancer: Lung Cancer. 110:53~55 (4.294)
2017 SCI-E Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance: PloS one. 12:e0181758~e0181758 (2.806)
2017 SCI-E Diffusion tensor imaging of normal-appearing white matter in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.: European Journal of Neurology. 24(7):966~973 (3.988)
2017 기타 Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder: Neurol Neuroimmunol Neuroinflamm. 4:e343~e343 ()
2017 SCI-E Normal-appearing white matter demyelination in neuromyelitis optica spectrum disorder: European journal of neurology. 24(4):652~658 (3.988)
2017 SCI Rituximab in Neuromyelitis Optica Spectrum Disorders: Why Not as First-Line Therapy: JAMA neurology. 74(4):482~482 (10.029)
2017 SCI-E Large-scale in-house cell-based assay for evaluating the serostatus in patients with neuromyelitis optica spectrum disorder based on new diagnostic criteria: Journal of clinical neurology. 13(2):175~180 (2.593)
2017 SCI Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders: Multiple Sclerosis. 23(3):413~419 (4.84)
2017 SCI Glatiramer acetate attenuates the activation of CD4+ T cells by modulating STAT1 and -3 signaling in glia: Scientific Reports. 7:40484~40484 (4.259)
2016 SCI-E Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis.: European journal of Neurology. 24(2):437~445 (3.956)
2016 SCI Response to letter regarding article 'Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder: Multiple Sclerosis. 23(2):304~305 (4.671)
2016 SCI-E Occurrence of asymptomatic acute neuromyelitis optica spectrum disorder-typical brain lesions during an attack of optic neuritis or myelitis: PLOS ONE. 11(12):e0167783~e0167783 (3.057)
2016 SCI Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis.: Multiple Sclerosis Journal. 22(14):1850~1858 (4.671)
2016 SCI-E Disease Type- and Status-Specific Alteration of CSF Metabolome Coordinated with Clinical Parameters in Inflammatory Demyelinating Diseases of CNS: Plos One. 11(11):e0166277~e0166277 (3.057)
2016 SCI-E Severe relapse after cessation of immunosuppressive therapy in a patient with neuromyelitis optica spectrum disorder: The Neurologist. 21(6):97~98 (0.875)
2016 SCI Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies: Journal of neurology, neurosurgery, psychiatry. 87(11):1257~1259 (6.431)
2016 SCI-E Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis: Clinica Chimica Acta. 462:118~126 (2.799)
2016 SCI Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder.: Multiple sclerosis : clinical and laboratory research.. 22(12):1616~1620 (4.671)
2016 SCI-E Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder.: European Journal of Neurology. 23(7):1165~1173 (3.956)
2016 SCI Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder: Journal of Neurology. 263(7):1343~1348 (3.408)
2016 SCI Central nervous system neuroinflammatory isorders in Asian/Pacific regions: Current Opinion in Neurology. 29(3):372~380 (4.469)
2016 SCI Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder: Neurology. 86(19):1772~1779 (8.166)
2016 SCI-E Cerebral cortex involvement in neuromyelitis optica spectrum disorder: Journal of clinical neurology. 12(2):188~193 (1.876)
2016 SCI-E Successful tratment of Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4-diaminopyridine: A case report: Oncology letters. 11(3):1933~1935 (1.482)
2016 SCI Leptomeningeal metastasis: clinical experience of 519 cases: European journal of cancer. 56:107~114 (6.163)
2016 SCI-E Acute disseminated encephalomyelitis with tremor as the initial symptom: Neurology Asia. 21(1):89~91 (0.196)
2015 SCI Placebo-controlled study in neuromyelitis optica-Ethical and design considerations: Multiple Sclerosis Journal. 22(7):862~872 (4.822)
2015 SCI Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints: Multiple sclerosis. 22(3):329~339 (4.822)
2015 SCI-E Increased frequency and severity of restless legs syndrome in patients with neuromyelitis optica spectrum disorder: Sleep medicine. 17:121~123 (3.154)
2015 SCI Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes: Journal of Neurology. 263(1):140~149 (3.377)
2015 SCI Bright spotty lesions on the spinal cord: an additional MRI indicator of neuromyelitis optica spectrum disorder?: Journal of neurology, neurosurgery, and psychiatry. 86:1280~1282 (6.807)
2015 SCI Tumefactive demyelinating lesions as a first clinical event: clinical, imaging, and follow-up observations: Journal of the Neurological Science. 358:118~124 (2.474)
2015 SCI Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab: JAMA Neurology. 72(9):989~995 (7.271)
2015 기타 Significant improvement of spasticity with intrathecal baclofen pump implantation in a patient with multiple sclerosis: Journal of multiple sclerosis. 6(2):40~43 (0)
2015 기타 Update on biomarkers in neuromyelitis optica: Neurology Neuroimmunology Neuroinflammation. 2:e134~e134 (0)
2015 SCI Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder: JAMA neurology. 72(7):815~822 (7.271)
2015 SCI-E The etiological spectrum of acute sensory myelitis: Journal of clinical neurology. 11(3):227~233 (1.7)
2015 SCI-E Utility of the rio score and modified rio score in korean patients with multiple sclerosis: PloS one. Online:Published (3.234)
2015 SCI Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis: Multiple sclerosis. 21(6):710~717 (4.822)
2015 SCI Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography: Multiple sclerosis. 21(6):678~688 (4.822)
2015 SCI Teaching NeuroImages: Periventricular restricted diffusion MRI in CMV ventriculitis: Neurology. 84(16):e121~e121 (8.286)
2015 기타 Healthcare costs of multiple sclerosis in Korea according to the level of disability.: Journal of Multiple Sclerosis(대한다발성경화증학회지). 6(1):9~13 (0)
2015 기타 The strategy of treatment of neuromyelitis optica spectrum disorder: Journal of Multiple Sclerosis. 6(1):1~8 (0)
2015 SCI MRI characteristics of neuromyelitis optica spectrum disorder: An international update: Neurology. 84(11):1165~1173 (8.286)
2015 SCI Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder: Journal of Neurology. 262:696~700 (3.377)
2015 SCI-E Oral disease-modifying therapies for multiple sclerosis: Journal of clinical neurology. 11(1):9~19 (1.7)
2014 SCI-E Diffuse cerebral vasospasm with infarct after intrathecal cytarabine in childhood leukemia: Pediatrics international. 56(6):921~924 (0.731)
2014 SCI The onset location of neuromyelitis optica spectrum disorder predicts the location of subsequent relapses.: Multiple sclerosis. 20(14):1908~1911 (4.863)
2014 SCI Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder: JAMA neurology. 71(11):1372~1378 (7.008)
2014 SCI-E A longitudinal brain magnetic resonance imaging study of neuromyelitis optica spectrum disorder: PloS one. 9(9):e108320~e108320 (3.534)
2014 SCI 6-Methoxyflavone inhibits NFAT translocation into the nucleus and suppresses T cell activation: The Journal of immunology. 193(6):2772~2783 (5.362)
2014 SCI Clinical and genetic aspects in twelve korean patients with adrenomyeloneuropathy: Yensei Medical Journal. 55(3):676~682 (1.263)
2014 SCI-E CD58 polymorphisms associated with the risk of neuromyelitis optica in a Korean population: BMC Neurology. 14(57):1~6 (2.486)
2014 기타 Cerebral adrenomyeloneuropathy clinically mimicking primary progressive multiple sclerosis: Journal of Multiple Sclerosis. 5(1):22~24 (0)
2014 기타 The systemic rheumatologic disease and neuromyelitis optica: Journal of Rheumatic Diseases. 21(1):4~8 (0)
2014 SCI Lack of association between AQP4 polymorphisms and risk of inflammatory demyelinating disease in a Korean population.: Gene. 536(2):302~307 (2.082)
2014 SCI Comment on "Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica.": Neurology. 82(6):546~547 (8.303)
2014 SCI Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica.: Neurology. 82:546~547 (8.303)
2014 SCI-E Association analysis of IL7R polymorphisms with inflammatory demyelinating diseases: Molecular medicine reports. 9(2):737~743 (1.484)
2014 SCI Steroid-resistant relapsing IgG4-related pachymeningitis treated with methotrexate: JAMA Neurol. 71(2):222~225 (7.008)
2014 SCI Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis: Multiple sclerosis. 20(9):1217~1223 (4.863)
2013 SCI The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders: Multiple Sclerosis Journal. 20(6):695~704 (4.863)
2013 SCI-E Validity of Korean Versions of the Multiple Sclerosis Impact Scale and the Multiple Sclerosis International Quality of Life Questionnaire: Journal of Clinical Neurology. 10(2):148~156 (1.807)
2013 SCI Evaluation of McDonald MRI criteria for dissemination in space in Korean patients with clinically isolated syndromes.: Multiple Sclerosis. 20(4):492~495 (4.863)
2013 SCI Putative association of GPC5 polymorphism with the risk of inflammatory demyelinating diseases.: Journal of Neurological Science. 335:82~88 (2.243)
2013 SCI Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations?: Multiple Sclerosis. 19(11):1493~1498 (4.472)
2013 SCI A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder: JAMA neurology. 70(9):1110~1117 (7.685)
2013 SCI A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica): multiple sclerosis. 19(10):1371~1380 (4.472)
2013 SCI-E Lack of association between CD226 genetic variants and inflammatory demyelinating diseases in Korean population: Neuroendoclinology Letters. 34(5):402~408 (0.932)
2013 SCI Associations of CD6, TNFRSF1A, and IRF8 polymorphisms with risk of inflammatory demyelinating diseases: Neuropathology and Applied Neurobiology. 39(5):519~530 (4.837)
2013 SCI-E Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab: European Journal of Neurology. 20(6):975~980 (4.162)
2013 SCI Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation: Annals of Neurology. 73(3):341~354 (11.193)
2013 SCI-E Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and Effects on Circulating Anti-Aquaporin-4 Antibody Levels: Journal of Clinical Neurology. 9(1):36~42 (1.892)
2012 기타 Brain Abnormalities in Neuromyelitis Optica Spectrum Disorder: Multiple Sclerosis International. 2012:735486~735486 (0)
2012 기타 Burden of Disease of Multiple Sclerosis in Korea: Epidemiology and Health. 34:120008~120008 (0)
2012 SCI Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?: Multiple Sclerosis. 18(10):1480~1483 (4.255)
2012 SCI Central nervous system aquaporin-4 autoimmunity presenting with an isolated cerebral abnormality.: Multiple Sclerosis. 18(9):1340~1343 (4.255)
2012 SCI Lack of response to rituximab therapy in patients with neuromyelitis optica: True non-responders or insufficient treatment?: Journal of Neurological Science. 319(1-2):171~172 (2.353)
2012 SCI Influence of pregnancy on neuromyelitis optica spectrum disorder: Neurology. 78(16):1264~1267 (8.312)
2012 SCI Clinical spectrum of CNS aquaporin-4 autoimmunity: Neurology. 78(15):1179~1185 (8.312)
2011 SCI Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4: Multiple Sclerosis. 18(5):578~586 (4.255)
2011 SCI Human Brain Endothelial Cell-derived COX-2 Facilitates Extravasation of Breast Cancer Cells across the Blood-brain Barrier: Anticancer Research. 31(12):4307~4313 (1.656)
2011 SCI Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years: Archives of Neurology. 68(11):1412~1420 (7.108)
2011 SCI Single-Dose Versus Fractionated Stereotactic Radiotherapy for Brain Metastases: International Journal of Radiation Oncology, Biology and Physics. 81(2):483~489 (4.503)
2011 SCI-E New Insights into Neuromyelitis Optica: Journal of Clinical Neurology. 7:115~127 (1.097)
2011 기타 Current Treatment Approaches for Neuromyelitis Optica: 대한다발성경화증학회지. 2:45~51 (0)
2011 SCI Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder: Multiple Sclerosis Journal. 17:1107~1112 (4.23)
2011 SCI Use of Mitoxantrone in Neuromyelitis Optica-Reply: Archives of Neurology. 68:1086~1087 (7.108)
2011 SCI-E Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels: Journal of Clinical Neuroscience. 18(7):997~998 (1.165)
2011 SCI Efficacy and Safety of Mitoxantrone in Patients With Highly Relapsing Neuromyelitis Optica: Archives of Neurology. 68(4):473~479 (7.108)
2011 SCI Tumefactive demyelination, an uncommon form of tacrolimus neurotoxicity.: Neurology. 76(7):672~674 (8.017)
2011 SCI Relapsing demyelinating CNS disease in a Korean pediatric population: Multiple sclerosis versus neuromyelitis optica: Multiple Sclerosis. 17(1):67~73 (4.23)
2010 SCI Prevalence of multiple sclerosis in Korea.: Neurology. 75(16):1432~1438 (8.172)
2010 SCI Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity.: Multiple Sclerosis. 16(10):1229~1236 (3.279)
2010 SCI Familial Neuromyelitis Optica: Neurology. 75(4):310~315 (8.172)
2010 SCI-E Lack of association between PRNP M129V polymorphism and multiple sclerosis, mild cognitive impairment, alcoholism and schizophrenia in a Korean population: Disease Markers. 28(5):315~321 (2.026)
2010 SCI Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica: Neurobiology of Disease. 37(2):349~355 (4.518)
2010 SCI-E F-18 fluorodeoxyglucose and F-18 fluorothymidine positron emission tomography/computed tomography imaging in a case of neurosarcoidosis.: Clinical Nuclear Medicine. 35:67~70 (3.915)
2009 SCI Brain abnormalities in Sjorgren syndrome with recurrent CNS manifestations: association with neuromyelitis optica.: Multiple Sclerosis. 15:1069~1076 (3.312)
2009 SCI-E Multiple sclerosis: Journal of Korean Medical Association (대한의학협회지). 52:665~676 (0)
2008 기타 Emerging new therapies in multiple sclerosis: Journal of Korean Neurological Association. 26:260~267 ()
2007 기타 Recent update of multiple sclerosis and neuromyelitis optica: Journal of Korean Neurological Association. 25:184~188 ()
2007 SCI Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.: Journal of Immunology. 178:6092~6099 (6.293)
2006 기타 Immunpathogenenic mechanism based treatment of multiple sclerosis: Hanyang Medical Review. 1:69~76 ()
2006 기타 Pathogenesis of multiple sclerosis: Journal of Korean Neurological Association. 24:57~63 ()
2006 SCI Natalizumab effect on immune cell responses in multiple sclerosis: Annals of Neurology. 59:748~754 (7.571)
2004 SCI Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis: Journal of Immunology. 172:7144~7153 (6.486)
2004 SCI Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients: Clinical Immunology. 111:38~46 (3.034)
2003 SCI Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis: Brain. 126:2738~2749 (7.976)
2003 SCI Neurologic Complications of Human Immunodeficiency Virus-type 1 Infection in Korea: Journal of Korean Medical Science. 18:149~157 (0.633)
2003 SCI Differential Effects of Th1 and Th2 Lymphocyte Supernatants Upon Human Microglia: Glia. 42:36~45 (4.677)
2002 SCI Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand: Clinical Immunology. 104:104~114 (2.564)
2000 SCI Hemimasticatory Spasm Associated with Localized Scleroderma and Facial Hemiatropy: Archives of Neurology. 57:576~580 (4.336)
2000 기타 Adult-onset Moyamoya Disease : Clinical Features and Prognosis: Journal of Korean Neurological Association. 18:1~7 ()
2000 기타 AIDS Dementia Complex : Report of an Autopsy Case: Journal of Korean Neurological Association. 18:472~475 ()
2000 SCI Kaposi's sarcoma herpesvirus-associated Castleman's disease with POEMS syndrome: Muscle & Nerve. 23:436~439 (2.45)
1999 기타 Differentiation of idiopathic acute transverse myelitis from myelopathic multiple sclerosis by MRI: Journal of Korean Neurological Association. 17:651~660 ()
1999 SCI Experimental Autoimmuine Myasthenia Gravis and CD5+ B-lymphocyte Expression: Journal of Korean Medical Science. 14:623~628 ()
1999 기타 Neurologic Manifestations of Churg-Strauss syndrome.: Journal of Korean Neurological Association. 17:836~840 ()
1999 기타 Histopathologic Features and CD5+ B-lymphocyte Expression in the Experimental Allergic Neuritis: Journal of Korean Society for Clinical Neurophysiology. 2:23~31 ()
1999 기타 Characteristics of Thymic Tumor-associated Myasthenia Gravis: Archives of Seoul National University Library. 1:1~37 ()
1999 기타 The Late Blink Reflex Response in Patients with Thalamic Hemorrhage: Journal of Korean Neurological Association. 17:661~667 ()
1998 SCI Acetazoamide-responsive Hereditary Paroxysmal Ataxia: Journal of Korean Medical Science. 13:196~2000 ()
1997 기타 Polymyositis Presenting with Respiratory Failure: Journal of Korean Neurological Association. 15:926~930 ()
1996 기타 Two Cases of WEBINO Syndrome: Journal of Korean Neurological Association. 14:612~619 ()
